Key Highlights

  • Quest Diagnostics (NYSE:DGX) fell 0.04% to USD 234.91 on Tuesday, October 20, with a Bollinger band width of 4.98%, an average true range of 2.15% and a market capitalization of USD 25.93 billion.
  • Quest Diagnostics' Bollinger band width of 4.98% and daily range of 2.15% show a compressed range in a USD 234.91 stock that jumped about USD 16 to USD 226 on July 23 after second-quarter revenue rose 10.2% to USD 3.04 billion.
  • Requisitions rose 13.1%, or 4.1% excluding the Corewell Health and Fresenius Medical Care relationships, demand was broad across physician, hospital and consumer channels, reported EPS was USD 2.84, up 15%, and favorable tax contingencies kept the full-year adjusted tax rate in line with 2025.
  • The next catalyst is third-quarter results on October 22, and investors will focus on volume growth, margins and fuel costs.

Squeeze Setup and Latest Developments

Quest Diagnostics' Bollinger band width of 4.98% and daily range of 2.15% show a compressed range in a USD 234.91 stock that jumped about USD 16 to USD 226 on July 23 after second-quarter revenue rose 10.2% to USD 3.04 billion, adjusted EPS rose 19.1% to USD 3.12 against roughly USD 2.82 expected, and the company raised 2026 guidance to USD 11.95 billion to USD 12.05 billion of revenue and USD 11.05 to USD 11.25 of adjusted EPS. Requisitions rose 13.1%, or 4.1% excluding the Corewell Health and Fresenius Medical Care relationships, demand was broad across physician, hospital and consumer channels, reported EPS was USD 2.84, up 15%, and favorable tax contingencies kept the full-year adjusted tax rate in line with 2025. On the call management said guidance excludes acquisitions and includes higher second-half fuel costs, expects the dilutive margin effect of the Corewell and Fresenius volumes to ease as it laps them in the fourth quarter, and supports the RESULTS Act on market data collection, with third-quarter results due before the open on October 22 against a USD 2.85 EPS consensus. Low-volatility readings cluster in large-cap industrials, banks and quality compounders as markets paused after last week's AI-driven selloff and Monday's rebound, with a heavy earnings week ahead that includes Netflix, SpaceX, Tesla and Meta.

Technical Setup and Management Commentary

A Bollinger band width of 4.98% and an average true range of 2.15% mean recent price swings are small relative to history, with a market value of USD 25.93 billion. A Bollinger band width of 4.98% means the bands drawn around the 20-day average sit close together, a classic marker of compressed volatility after a period of narrow trading. An average true range of 2.15% of price means the typical daily range is small, so a move beyond recent bands would register as a meaningful change in behavior. Squeeze setups often precede larger moves, but they do not indicate direction, so catalysts such as earnings, guidance, rates or macro data decide which way volatility expands.

Risks and What to Watch

Squeeze conditions show compressed volatility rather than direction, and earnings, guidance, rates or macro data can end them abruptly in either direction. What to watch next: volume growth, margins and fuel costs. This is information only and not investment advice.

Where Things Stand

Quest Diagnostics (NYSE:DGX) remains in focus as compressed trading volatility. A compressed Bollinger band width shows low recent volatility but not direction, so the next earnings date, guidance and macro data matter more than the squeeze reading. Investors should weigh the next catalyst, volume growth, margins and fuel costs, against balance sheet strength, funding conditions and the direction of Treasury yields. Follow-through volume and any company filing will determine whether the move holds. Each figure should be cross-checked against the underlying filings and live quotes. Direction remains uncertain, and this analysis is informational and does not constitute investment advice.